Longeveron Q2 net loss widens on higher legal, clinical trial costs - LGVN News | RalliesLongeveron Q2 net loss widens on higher legal, clinical trial costs
L
LGVN• Outlook
- Topline results from Phase 2b ELPIS II trial in HLHS expected in September 2026
- Company expects to begin planning Phase 2 PDCM trial in 2026, with initiation in 2027
- Longeveron expects current cash to fund operations into Q4 2026; seeking additional financing
Overview
- US biotech firm's Q2 revenue fell 10% yr/yr, mainly due to lower contract manufacturing income
- Net loss for Q2 widened 22% yr/yr, driven by higher legal and clinical trial costs
- Gross profit for Q2 rose 25% yr/yr, despite declining revenue
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Loss Per Share | | $0.19 | |
| Q2 Net Loss | | $6.07 mln | |
| Q2 Gross Profit | | $182,000 | |
| Q2 Income from Operations | | -$6.17 mln | |
| Q2 Operating Expenses | | $6.35 mln | |
Result Drivers
- Contract manufacturing drop - Q2 revenue fell due to absence of contract manufacturing services
